NCNMGF
KYTX icon

Nano-Cap New Millennium Growth Fund’s Kyverna Therapeutics KYTX Stock Holding History

Nano-Cap New Millennium Growth Fund’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$624K Buy
70,000
+18,000
+35% +$160K 0.48% 74
2026
Q1 		$449K Sell
52,000
-1,500
-3% -$12.5K 0.42% 81
2025
Q4 		$503K Buy
+53,500
New +$397K 0.43% 79

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.32B AUM 1.62% 1-Year Est. Return

Nano-Cap New Millennium Growth Fund's KYTX Position: Q2 2026 in Review

Nano-Cap New Millennium Growth Fund increased its Kyverna Therapeutics (KYTX) stake by 35% in Q2 2026, buying an estimated $160K and bringing the position to 70,000 shares worth $624K. The position accounts for 0.48% of the portfolio, ranked #74.

Nano-Cap New Millennium Growth Fund first reported a position in KYTX in Q4 2025 and has held it in 3 quarters since. 120 funds tracked by Wall St. Rank hold KYTX as of Q2 2026.

  • Nano-Cap New Millennium Growth Fund held 70,000 shares of Kyverna Therapeutics worth $624K as of Q2 2026.
  • Nano-Cap New Millennium Growth Fund bought 18,000 Kyverna Therapeutics shares in Q2 2026, an estimated $160K.
  • Kyverna Therapeutics made up 0.48% of Nano-Cap New Millennium Growth Fund's portfolio in Q2 2026, its #74 holding.
  • Nano-Cap New Millennium Growth Fund first reported a position in Kyverna Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 120 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2026.

Based on Nano-Cap New Millennium Growth Fund's 13F filing for Q2 2026, filed 14 Aug 2026.